Dynamic Assessment of ctDNA in Patients With Cervical and Anal Canal Tumors to Optimize Follow-up and Clinical Outcomes in the Brazilian Unified Health System (SUS)
Latest Information Update: 17 Oct 2024
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Anal cancer; Cervical cancer
- Focus Therapeutic Use
- 17 Oct 2024 New trial record